---
title: "Zelgen: Clinical trials for injectable ZG005, injectable ZGGS18, and hydrochloride gilteritinib tablets combined for advanced solid tumors have been approved"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253972031.md"
description: "Zelgen recently received approval from the National Medical Products Administration to conduct clinical trials for the combination of injectable ZG005, ZGGS18, and JAK inhibitor hydrochloride tablets for advanced solid tumors. ZG005 is an innovative tumor immunotherapy biological product and one of the first drugs targeting the same site to enter clinical research globally; ZGGS18 is a bifunctional antibody fusion protein with the potential to treat solid tumors; JAK inhibitor hydrochloride is a novel dual inhibitor of JAK and ACVR1 with independent intellectual property rights"
datetime: "2025-08-21T11:01:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253972031.md)
  - [en](https://longbridge.com/en/news/253972031.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253972031.md)
---

# Zelgen: Clinical trials for injectable ZG005, injectable ZGGS18, and hydrochloride gilteritinib tablets combined for advanced solid tumors have been approved

According to the Zhitong Finance APP, Zelgen (688266.SH) announced that it recently received the "Notice of Approval for Drug Clinical Trials" issued by the National Medical Products Administration (referred to as "NMPA"). The clinical trials for injectable ZG005, injectable ZGGS18, and the combination of hydrochloride gilteritinib tablets for advanced solid tumors have been approved.

The announcement shows that injectable ZG005 is a recombinant humanized anti-PD-1/TIGIT bispecific antibody, an innovative tumor immunotherapy biological product, classified as Category 1, and is expected to be used for the treatment of various solid tumors. According to public inquiries, ZG005 is one of the first drugs in the world to enter clinical research targeting the same site, and currently, no similar mechanism drugs have been approved for marketing globally. Injectable ZGGS18 is a recombinant humanized anti-VEGF/TGF-β bifunctional antibody fusion protein, classified as a Category 1 therapeutic biological product, and is expected to become an innovative biological product for the treatment of solid tumors. Hydrochloride gilteritinib (formerly known as hydrochloride jakinib) is a new type of JAK and ACVR1 dual inhibitor developed independently by the company, classified as a Category 1 new drug, and the company holds independent intellectual property rights for this product

### Related Stocks

- [688266.CN](https://longbridge.com/en/quote/688266.CN.md)

## Related News & Research

- [Just 4% of fund managers see a hard landing - BofA survey](https://longbridge.com/en/news/286866256.md)
- [The Limits of Limit Orders in Retail FX/CFD Trading](https://longbridge.com/en/news/287126072.md)
- [Akastor's (OB:AKAST) Sluggish Earnings Might Be Just The Beginning Of Its Problems](https://longbridge.com/en/news/287157146.md)
- [Weak Statutory Earnings May Not Tell The Whole Story For Züblin Immobilien Holding (VTX:ZUBN)](https://longbridge.com/en/news/287156745.md)
- [Discount Investment's (TLV:DISI) Earnings Are Of Questionable Quality](https://longbridge.com/en/news/287157597.md)